## Resection of Hepatic and Pulmonary Metastases in Patients with Colorectal Carcinoma W e read with interest the article by Ambiru et al. 1 concerning the resection of colorectal hepatic and pulmonary metastases. In a population of 156 patients with resected hepatic metastases from colorectal car
Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma
β Scribed by Satoshi Ambiru; Masaru Miyazaki; Hiroshi Ito; Koji Nakagawa; Hiroaki Shimizu; Atsushi Kato; Shunta Nakamura; Hideyuki Omoto; Nobuyuki Nakajima
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 68 KB
- Volume
- 82
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Hideyuki Omoto, M.D.
RESULTS. Five of the patients included four who underwent pulmonary resection
Nobuyuki Nakajima, M.D.
for pulmonary metastases after initial hepatic resection for hepatic metastases and one patient who underwent hepatic metastasis resection after initial pulmonary The First Department of Surgery, Chiba Univermetastasis resection. One additional patient underwent a simultaneous resection sity School of Medicine, Chiba, Japan.
of hepatic and pulmonary metastases. The median interval between the 2 resections was 23 months. The median follow-up was 32 months after the second resection. At the time of last follow-up, 4 patients were alive and free of recurrent disease at 6, 7, 38, and 64 months, respectively, after their second resection. The remaining 2 patients died of disease at 17 and 32 months, respectively, after the second surgery.
CONCLUSIONS.
The results of the current study suggest that hepatic and pulmonary resection can result in long term survival in select patients with hepatic and pulmonary metastases from colorectal carcinoma because surgery remains the only potentially curative treatment.
π SIMILAR VOLUMES
## BACKGROUND. More than 40% of patients who undergo curative resection of advanced colorectal carcinoma can be expected to have recurrence of the disease. The most frequent sites of recurrence are the liver (33% of patients) and lung (22%). Interest has therefore focused on treating hepatic or
The data used in this article were accrued during the authors' appointment at the Memorial Sloan-Kettering Cancer Center (MSKCC), but the opinions expressed herein are their own and do not necessarily reflect the current treatment policy of MSKCC.